US Stock Market Move | Moderna (MRNA.US) plans to issue $2 billion in convertible senior notes, and its stock has dropped over 5%.
On Thursday, Moderna (MRNA.US) opened lower and continued to decline. As of the time of this report, it had fallen more than 5%, with a market value of approximately $56.6 billion.
On Thursday, Moderna (MRNA.US) opened lower and continued to decline, with a drop of over 5% as of the time of publication, bringing its market value to approximately $56.6 billion. In terms of news, Moderna will issue $2 billion worth of convertible senior notes. Previously, Moderna and Merck & Co., Inc. jointly announced that their individualized cancer vaccine intismeran in combination with Keytruda (pembrolizumab) achieved both of the primary endpointsrecurrence-free survival (RFS) and distant metastasis-free survival (DMFS)in the Phase III trial INTerpath-001 for completely resected stage IIB to IV melanoma. Over the past week, the stock has recorded an increase of nearly 130%.
Related Articles
HK Stock Market Move | PCB concept stocks rose across the board as PCB manufacturers collectively announced price increases. Analysts indicate that the performance slope in the third quarter is expected to accelerate.
HK Stock Market Move | REFIRE (02570) plummeted over 20%, hitting a new low since its listing. It will officially be removed from the Hong Kong Stock Connect list starting today.
HK Stock Market Move | KINTOR PHARMA-B (09939) surged over 7% as the long-term safety trial of KT-939 has been successfully completed, and the company is actively advancing the related registration application work.
HK Stock Market Move | PCB concept stocks rose across the board as PCB manufacturers collectively announced price increases. Analysts indicate that the performance slope in the third quarter is expected to accelerate.
HK Stock Market Move | REFIRE (02570) plummeted over 20%, hitting a new low since its listing. It will officially be removed from the Hong Kong Stock Connect list starting today.
HK Stock Market Move | KINTOR PHARMA-B (09939) surged over 7% as the long-term safety trial of KT-939 has been successfully completed, and the company is actively advancing the related registration application work.
RECOMMEND
